免疫表型能指导髓系恶性肿瘤患者的分子分析吗

C. Giatra, Eirini Tziotziou, K. Psarra, M. Garofalaki, E. Grigoriou, S. Karakatsanis, Evaggelia Nikolou, S. Delimpasi, T. Tzenou, S. Gigantes, I. Baltadakis, D. Karakasis, I. Tsonis, V. Kapsimali, F. Kontopidou, M. Pagoni, T. Karmiris, A. Tsirogianni, N. Harhalakis
{"title":"免疫表型能指导髓系恶性肿瘤患者的分子分析吗","authors":"C. Giatra, Eirini Tziotziou, K. Psarra, M. Garofalaki, E. Grigoriou, S. Karakatsanis, Evaggelia Nikolou, S. Delimpasi, T. Tzenou, S. Gigantes, I. Baltadakis, D. Karakasis, I. Tsonis, V. Kapsimali, F. Kontopidou, M. Pagoni, T. Karmiris, A. Tsirogianni, N. Harhalakis","doi":"10.2015/HC.V14I1.860","DOIUrl":null,"url":null,"abstract":"OBjeCTive: Immunophenotype has been correlated with molecular aberrations in several studies. The aim of this study was the discovery of immunophenotypic features related to mutations in AML and MDS patients connected to prognostic factors. Moreover, an effort to evaluate a method for the detection of the most common Nucleophosmin (NPM1) mutations of exon12 and Internal Tandem Duplications (ITD) mutations of FLT3 gene by flow cytometry was performed. MeThOd: Patients with de novo myeloid neoplasms [AML and MDS (AML-M3 patients were excluded)] were included. FLT3/ITD/TKD and NPM1 mutations were detected by PCR and fragment analysis. The immunophenotypic analysis was performed by multi-dimensional flow cytometry (FC) with a standardized panel of monoclonal antibodies on peripheral blood or bone marrow samples. Nucleophosmin Antibody and CD135 were used for the mutations immunophenotypic detection. ReSulTS: NPM1 and/or FLT3 mutations correlated with low or no expression of more immature cells markers such as CD34, CD117, HLADR, as well as higher expression of more mature markers such as CD11b. The higher expression of CD33 should be mentioned as well. The presence of NPM1mut and FLT3/ITD does not seem to be detectable by FC at least using these two monoclonal antibodies. The presence of CD7 aberrant lymphoid marker’s expression was associated with FLT3mut, NPM1wt genotype. CD56 or CD2 positivity was found only in patients’ samples negative for NPM1 and/or FLT3 mutations. COnCluSiOnS: Certain immunophenotype findings including the presence of aberrant lymphoid markers may be indicative of the presence of mutations in NPM1 and FLT3 linked to prognosis. ORiginAl ARTiCle Department of HaematologyLymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, Greece Department of Immunology and Histocompatibility, “Evangelismos” General Hospital of Athens, Greece Haematology Department, Hippocratio Hospital Athens Greece, National and Kapodistrian University of Athens Microbiology and Immunology Department, National and Kapodistrian University of Athens Haematology Unit of the 3 Internal Medicine Clinic, Sotiria General Hospital Athens Medical School, Athens Greece HOSPITAL CHRONICLES 2019, 14(1): 13–23 Correspondence to: Eirini Tziotziou, Department of Molecular Biology Lab, Department of Haematology-Lymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, 45-47, Ipsilandou street, 10676 Athens, Greece Tel.: +3","PeriodicalId":91266,"journal":{"name":"Hospital chronicles = Nosokomeiaka chronika","volume":"14 1","pages":"13-23"},"PeriodicalIF":0.0000,"publicationDate":"2019-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Could Immunophenotype Guide Molecular Analysis in Patients with Myeloid Malignancies\",\"authors\":\"C. Giatra, Eirini Tziotziou, K. Psarra, M. Garofalaki, E. Grigoriou, S. Karakatsanis, Evaggelia Nikolou, S. Delimpasi, T. Tzenou, S. Gigantes, I. Baltadakis, D. Karakasis, I. Tsonis, V. Kapsimali, F. Kontopidou, M. Pagoni, T. Karmiris, A. Tsirogianni, N. Harhalakis\",\"doi\":\"10.2015/HC.V14I1.860\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"OBjeCTive: Immunophenotype has been correlated with molecular aberrations in several studies. The aim of this study was the discovery of immunophenotypic features related to mutations in AML and MDS patients connected to prognostic factors. Moreover, an effort to evaluate a method for the detection of the most common Nucleophosmin (NPM1) mutations of exon12 and Internal Tandem Duplications (ITD) mutations of FLT3 gene by flow cytometry was performed. MeThOd: Patients with de novo myeloid neoplasms [AML and MDS (AML-M3 patients were excluded)] were included. FLT3/ITD/TKD and NPM1 mutations were detected by PCR and fragment analysis. The immunophenotypic analysis was performed by multi-dimensional flow cytometry (FC) with a standardized panel of monoclonal antibodies on peripheral blood or bone marrow samples. Nucleophosmin Antibody and CD135 were used for the mutations immunophenotypic detection. ReSulTS: NPM1 and/or FLT3 mutations correlated with low or no expression of more immature cells markers such as CD34, CD117, HLADR, as well as higher expression of more mature markers such as CD11b. The higher expression of CD33 should be mentioned as well. The presence of NPM1mut and FLT3/ITD does not seem to be detectable by FC at least using these two monoclonal antibodies. The presence of CD7 aberrant lymphoid marker’s expression was associated with FLT3mut, NPM1wt genotype. CD56 or CD2 positivity was found only in patients’ samples negative for NPM1 and/or FLT3 mutations. COnCluSiOnS: Certain immunophenotype findings including the presence of aberrant lymphoid markers may be indicative of the presence of mutations in NPM1 and FLT3 linked to prognosis. ORiginAl ARTiCle Department of HaematologyLymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, Greece Department of Immunology and Histocompatibility, “Evangelismos” General Hospital of Athens, Greece Haematology Department, Hippocratio Hospital Athens Greece, National and Kapodistrian University of Athens Microbiology and Immunology Department, National and Kapodistrian University of Athens Haematology Unit of the 3 Internal Medicine Clinic, Sotiria General Hospital Athens Medical School, Athens Greece HOSPITAL CHRONICLES 2019, 14(1): 13–23 Correspondence to: Eirini Tziotziou, Department of Molecular Biology Lab, Department of Haematology-Lymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, 45-47, Ipsilandou street, 10676 Athens, Greece Tel.: +3\",\"PeriodicalId\":91266,\"journal\":{\"name\":\"Hospital chronicles = Nosokomeiaka chronika\",\"volume\":\"14 1\",\"pages\":\"13-23\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hospital chronicles = Nosokomeiaka chronika\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2015/HC.V14I1.860\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hospital chronicles = Nosokomeiaka chronika","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2015/HC.V14I1.860","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

OBjeCTive:在几项研究中,免疫表型与分子畸变有关。本研究的目的是发现AML和MDS患者与预后因素相关的突变的免疫表型特征。此外,通过流式细胞术对检测外显子12的最常见的NPM1突变和FLT3基因的内部串联重复(ITD)突变的方法进行了评估。MeThOd:包括新发髓系肿瘤[AML和MDS(AML-M3患者除外)]患者。通过PCR和片段分析检测FLT3/ITD/TKD和NPM1突变。免疫表型分析通过多维流式细胞术(FC)在外周血或骨髓样本上用标准化的单克隆抗体组进行。用核磷蛋白抗体和CD135进行突变的免疫表型检测。ReSulTS:NPM1和/或FLT3突变与较不成熟细胞标记物(如CD34、CD117、HLADR)的低表达或无表达以及较成熟标记物(例如CD11b)的高表达相关。CD33的高表达也应该被提及。至少使用这两种单克隆抗体,FC似乎无法检测到NPM1mut和FLT3/ITD的存在。CD7异常淋巴标志物的表达与FLT3mut、NPM1wt基因型有关。CD56或CD2阳性仅在NPM1和/或FLT3突变阴性的患者样本中发现。COnCluSiOnS:某些免疫表型发现,包括异常淋巴标志物的存在,可能表明NPM1和FLT3存在与预后相关的突变。ORigiAl ARTiCle血液科淋巴瘤和BMT室,“Evangelismos”雅典综合医院,希腊免疫学和组织相容性科,“Evangerismos”希腊雅典综合医院希腊血液科,希腊希波克拉提奥医院,雅典国立和卡波迪斯特里安大学微生物学和免疫学系,国立和Kapodistrian雅典大学3内科诊所血液科,Sotiria综合医院雅典医学院,雅典希腊医院2019,14(1):13-23通讯:Eirini Tziotziou,分子生物学实验室系,血液学系,淋巴瘤和BMT科,雅典“福音派”综合医院,45-47,Ipsilandou街,10676希腊雅典电话:+3
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Could Immunophenotype Guide Molecular Analysis in Patients with Myeloid Malignancies
OBjeCTive: Immunophenotype has been correlated with molecular aberrations in several studies. The aim of this study was the discovery of immunophenotypic features related to mutations in AML and MDS patients connected to prognostic factors. Moreover, an effort to evaluate a method for the detection of the most common Nucleophosmin (NPM1) mutations of exon12 and Internal Tandem Duplications (ITD) mutations of FLT3 gene by flow cytometry was performed. MeThOd: Patients with de novo myeloid neoplasms [AML and MDS (AML-M3 patients were excluded)] were included. FLT3/ITD/TKD and NPM1 mutations were detected by PCR and fragment analysis. The immunophenotypic analysis was performed by multi-dimensional flow cytometry (FC) with a standardized panel of monoclonal antibodies on peripheral blood or bone marrow samples. Nucleophosmin Antibody and CD135 were used for the mutations immunophenotypic detection. ReSulTS: NPM1 and/or FLT3 mutations correlated with low or no expression of more immature cells markers such as CD34, CD117, HLADR, as well as higher expression of more mature markers such as CD11b. The higher expression of CD33 should be mentioned as well. The presence of NPM1mut and FLT3/ITD does not seem to be detectable by FC at least using these two monoclonal antibodies. The presence of CD7 aberrant lymphoid marker’s expression was associated with FLT3mut, NPM1wt genotype. CD56 or CD2 positivity was found only in patients’ samples negative for NPM1 and/or FLT3 mutations. COnCluSiOnS: Certain immunophenotype findings including the presence of aberrant lymphoid markers may be indicative of the presence of mutations in NPM1 and FLT3 linked to prognosis. ORiginAl ARTiCle Department of HaematologyLymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, Greece Department of Immunology and Histocompatibility, “Evangelismos” General Hospital of Athens, Greece Haematology Department, Hippocratio Hospital Athens Greece, National and Kapodistrian University of Athens Microbiology and Immunology Department, National and Kapodistrian University of Athens Haematology Unit of the 3 Internal Medicine Clinic, Sotiria General Hospital Athens Medical School, Athens Greece HOSPITAL CHRONICLES 2019, 14(1): 13–23 Correspondence to: Eirini Tziotziou, Department of Molecular Biology Lab, Department of Haematology-Lymphomas and BMT Unit, “Evangelismos” General Hospital of Athens, 45-47, Ipsilandou street, 10676 Athens, Greece Tel.: +3
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信